Fosun Pharma subsidiary signs potential $1.9bn Pfizer licence deal

YP05002, developed by Yao Pharma, is in Phase 1 clinical development in Australia and can potentially help with metabolic diseases; Yao Pharma will receive an upfront payment of $150m for a worldwide licence.

Chongqing Yao Pharmaceutical Company (Yao Pharma) and Shanghai Fosun Pharmaceutical Industrial Development Company, both subsidiaries of Fosun Pharma, have entered into an exclusive collaboration and licence agreement with US pharmaceutical giant Pfizer, according to a December announcement.

¬ Haymarket Media Limited. All rights reserved.

Sign in to read on!

Registered users get 2 free articles in 30 days.

Subscribers have full unlimited access to FinanceAsia.

Not signed up? New users get 2 free articles per month, plus a 7-day unlimited free trial.

Questions?
See here for more information on licences and prices, or contact [email protected].

Share our publication on social media
Share our publication on social media